Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Open accessThe DOI matches its Crossref record; 230 of the 235 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and have long been considered incurable. Following the successful development of a gene augmentation therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different therapeutic approaches are currently being developed, in particular a large variety of molecular therapies. These are depending on the severity of the retinal degeneration, knowledge of the pathophysiological mechanism underlying each subtype of IRD, and the therapeutic target molecule. DNA therapies include approaches such as gene augmentation therapy, genome editing and optogenetics. For some genetic subtypes of IRD, RNA therapies and compound therapies have also shown considerable therapeutic potential. In this review, we summarize the current state-of-the-art of various therapeutic approaches, including the pros and cons of each strategy, and outline the future challenges that lie ahead in the combat against IRDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, another large gene, CEP290, can be rescued on the mRNA level by antisense oligonucleotides (AONs; QR-110 for Leber congenital amaurosis (LCA), with CEP290; QR-421a for LCA with USH2A) [19].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Neurodegenerative Disorders: Parkinson's Disease and Huntington's Disease
Hague, S., Klaffke, S., & Bandmann, O. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948961_0007 · Cited by 2,767
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414 · cited 1×
“To overcome this aspect, researchers have developed different strategies—(i) using ribonucleoproteins (RNPs) as a form of delivery [55]; (ii) titrating the concentration of gRNA and Cas9 or using two gRNAs flanking the target region [56]; (iii) adding two additional guanine bases at the 5’ end of the gRNA sequence for…”
BackgroundRNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093 · cited 1×
“Despite, the efficacy was comparable to that shown by iRNA, thus the substantially lower off-target ratio makes this approach well-suited for therapeutic applications [137].”
ResultKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017) · Science · doi:10.1126/science.aaq0180 · Cited by 1,834
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“…another subtype of inherited retinal disease that is caused by bi-allelic mutations in RPE65, has provided hope for many visually impaired individuals, and is paralleled by the development of similar therapeutic strategies for other genes underlying these disorders (Vazquez-Dominguez et al., 2019).”
BackgroundSelf-citationPontikos, N., Arno, G., Jurkute, N., Schiff, E., Ba-Abbad, R., Malka, S., Gimenez, A., Georgiou, M., Wright, G., Armengol, M., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.008 · Cited by 254
“Adenoassociated viruses have been a vector of choice for ocular gene therapy trials, targeting retinal cells with relatively low immunogenicity, but their capacity is limited.(5) We explored transcript lengths and relationships with numbers of families affected.”
BackgroundInfluentialHerrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
“Luxturna has established the safety and efficacy of gene augmentation via subretinal delivery, and, now, many different AAV gene therapies are under preclinical and/or clinical development (7, 8).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
Self-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“The company Ophthotech (now Iveric) explores the miniCEP290580–1180, a miniABCA4 (no published information available), and miniUSH2A (no published information available) for rAAV vector therapy.”
BackgroundInfluentialNanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
“Currently, the three main approaches to edit the genome are: zinc finger nucleases (ZFNs), tra scription activator-like effe tor nucleases (TALENs), both of which correct the mutations ex vivo and clustered regularly interspaced short palindromic repeats (CRISPR)— CRISPR associated (Cas9) system (CRISPR/Cas9) which ca…”
BackgroundGene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
“The double-strand breaks (DSBs) created by the enzyme subsequently activate one of the DNA repair pathways: non-homologous end joining (NHEJ), homology-directed repair (HDR), or microhomology-mediated and joining (40).”
BackgroundAdeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
Leroy, B. P., Birch, D. G., Duncan, J. L., Lam, B. L., Koenekoop, R. K., Porto, F. B. O., Russell, S. R., & Girach, A. (2021) · Retina · doi:10.1097/iae.0000000000003133 · Cited by 71
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“In comparison to ZFN and TALEN, the CRISPR/Cas system is regarded as a more sophisticated editing tool with several benefits, including the ease of design, increased effectiveness, and capacity to introduce mutations in many genes simultaneously [19].”
BackgroundGorbatyuk, M. S., Starr, C. R., & Gorbatyuk, O. S. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100860 · Cited by 56
Tomkiewicz, T. Z., Suárez-Herrera, N., Cremers, F. P. M., Collin, R. W. J., & Garanto, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094621 · Cited by 61
Self-citationThe need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement
ERN-EYE study group, Black, G. C. M., Sergouniotis, P. I., Sodi, A., Leroy, B. P., Cauwenbergh, C. V., Lišková, P., Grønskov, K., Klett, A., Kohl, S., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01756-x · Cited by 54
Fry, L. E., McClements, M. E., & MacLaren, R. E. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.6418 · Cited by 46
Sodi, A., Banfi, S., Testa, F., Della Corte, M., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
“Initially considered incurable, as the understanding of the pathophysiological mechanisms underlying the subtypes of IRD has expanded, a number of therapeutic approaches to treating IRDs have been proposed, the most advanced of which is gene supplementation therapy [6].”
BackgroundFocused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
“These include large genes such as ABCA4, CEP290 and some Usher genes, and dominant RP (reviewed in [176]).”
BackgroundSuga, A., Yoshitake, K., Minematsu, N., Tsunoda, K., Fujinami, K., Miyake, Y., Kuniyoshi, K., Hayashi, T., Mizobuchi, K., Ueno, S., et al. (2022) · Human Mutation · doi:10.1002/humu.24492 · Cited by 41
Retinal Organoids and Retinal Prostheses: An Overview
Bellapianta, A., Cetkovic, A., Bolz, M., & Salti, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062922 · Cited by 44
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
RNA-based therapies in inherited retinal diseases
Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., et al. (2022) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414221134602 · Cited by 36
“Act at the level of the RNA; do not alter DNA 32,35 No DSB generation Target the DNA; some can directly alter the genome; 5,39,40 Induces DSB Long half-life; require repeat dosing (in IRDs typically once or twice per year) 36,41 Potential for single treatment/dosing (per eye); Long-term expression…”
BackgroundMethodInfluentialRunhart, E. H., Dhooge, P. P. A., Meester‐Smoor, M. A., Pas, J. A. A. H., Pott, J. W. R., van Leeuwen, R., Kroes, H. Y., Bergen, A. A. B., de Jong‐Hesse, Y., Thiadens, A. A. H. J., et al. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14996 · Cited by 38
“(Vázquez-Domı́nguez et al. 2019) Prevalence data are relevant for the planning of clinical trials and are required for pharmacoeconomic evaluation of orphan drugs.”
BackgroundLohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
The Alter Retina: Alternative Splicing of Retinal Genes in Health and Disease
Aísa-Marín, I., García-Arroyo, R., Mirra, S., & Marfany, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041855 · Cited by 42
Conductance Mechanisms of Rapidly Desensitizing Cation Channelrhodopsins from Cryptophyte Algae
Sineshchekov, O. A., Govorunova, E. G., Li, H., Wang, Y., Melkonian, M., Wong, G. K., Brown, L. S., & Spudich, J. L. (2020) · mBio · doi:10.1128/mbio.00657-20 · Cited by 33
Inherited Eye Diseases with Retinal Manifestations through the Eyes of Homeobox Genes
Markitantova, Y. V., & Simirskii, V. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051602 · Cited by 33
“Advanced sequencing methods and the use of cell type-specific transcriptome and proteome and high-throughput screening systems of phenotypic and pleiotropic genetic effects analysis are aimed at identifying target genes associated with inherited diseases and provide prerequisites for better diagnostics, appropriate th…”
MethodRetinitis Pigmentosa and Allied Diseases
Alemán, T. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_1 · Cited by 32
Gallego, C., Gonçalves, M. A. F. V., & Wijnholds, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00838 · Cited by 27
Bellingrath, J.-S., McClements, M. E., Fischer, M. D., & MacLaren, R. E. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1092913 · Cited by 22
“While gene replacement therapy has proven to be a safe and effective therapy for IRDs, with an approved treatment for RPE-65-associated IRD now available and others being evaluated in clinical trial (Russell et al., 2017; Vazquez-Dominguez et al., 2019), an unmet therapeutic need remains for genes too large to fit int…”
BackgroundStargardt macular dystrophy and therapeutic approaches
Fujinami, K., Waheed, N. K., Laich, Y., Yang, P. G., Fujinami‐Yokokawa, Y., Higgins, J. J., Lu, J. T., Curtiss, D., Clary, C. M., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-323071 · Cited by 38
Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials
Wasnik, V. B., & Thool, A. R. (2022) · Cureus · doi:10.7759/cureus.29533 · Cited by 22
“The RPE65 gene encodes for retinoid isomerohydrolase, an enzyme of the visual cycle synthesized by the retinal pigment epithelium (RPE) [7,8].”
BackgroundInfluentialAngeli, P. D., Reuter, P., Hauser, S., Schöls, L. J., Štingl, K., Wissinger, B., & Kohl, S. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.023 · Cited by 29
Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing
Hernández-Juárez, J., Rodríguez‐Uribe, G., & Borooah, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.698521 · Cited by 22
“In order to overcome some of the limitations of gene supplementation therapy, genomic editing approaches have recently become of interest (28).”
BackgroundAdvancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 19
“, autosomal dominant, autosomal recessive, X-linked, and mitochondrial (5).”
BackgroundInfluentialDuncan, J. L., Bowman, A. N., Laster, A., Gelfman, C. M., Birch, D. G., Boye, S. L., Daiger, S. P., Priore, L. V. D., Zack, D. J., & Handa, J. T. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.28 · Cited by 17
Vázquez-Domínguez, I., Anido, A. A., Duijkers, L., Hoppenbrouwers, T., Hoogendoorn, A. D. M., Koster, C., Collin, R. W. J., & Garanto, A. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae686 · Cited by 13
“Therefore, AONs have been postulated as promising molecules to correct aberrant splicing in IRDs ( 6 ).”
Self-citationToulis, V., Cortés‐González, V., de Castro‐Miró, M., Sallum, J. M. F., Mora, J. C., Villanueva‐Mendoza, C., Ciccioli, M., Gonzàlez‐Duarte, R., Valero, R., & Marfany, G. (2020) · Genes · doi:10.3390/genes11040378 · Cited by 14
Faber, S., & Roepman, R. (2019) · Genes · doi:10.3390/genes10080557 · Cited by 16
Clinical and biochemical footprints of inherited metabolic disorders. VII. Ocular phenotypes
Garanto, A., Ferreira, C. R., Boon, C. J. F., van Karnebeek, C., & Blau, N. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.02.002 · Cited by 16
Self-citationDe Novo Mutations Contributes Approximately 7% of Pathogenicity in Inherited Eye Diseases
Li, W., He, X., Yang, Z., Han, D., Sun, Y., Chen, Y., Han, X., Guo, S., Ma, Y.-T., Jin, X., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.2.5 · Cited by 12
“38–43 In addition to rare inherited mutations, we propose that disease-causing DNMs may contribute to the genetic architecture of IEDs, which has not been well studied.”
Cetkovic, A., Bellapianta, A., Irimia‐Vladu, M., Hofinger, J., Yumusak, C., Corna, A., Scharber, M. C., Zeck, G. M., Sariçiftçi, N. S., Bolz, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158666 · Cited by 13
“Different therapeutic approaches are employed at early stages of the disease progression, such as gene replacement therapy and pharmacological treatment [2,3].”
BackgroundSather, R., Ihinger, J., Simmons, M., Khundkar, T., Lobo, G. P., & Montezuma, S. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310895 · Cited by 13
“Sci. 2023, 24, 10895 3 of 13 There are several therapeutic trials underway for the treatment of IRDs [17].”
BackgroundVázquez-Domínguez, I., Duijkers, L., Fadaie, Z., Alaerds, E. C. W., Post, M. A., van Oosten, E., O’Gorman, L., Kwint, M. P., Koolen, L., Hoogendoorn, A. D. M., et al. (2022) · Cells · doi:10.3390/cells11223640 · Cited by 11
“Inherited retinal diseases (IRDs) are a highly heterogenous group of neurodegenerative disorders leading to a visual impairment as a result of the progressive loss of photoreceptor and/or retinal pigment epithelium (RPE) cells [1].”
BackgroundInfluentialSelf-citationAlternative RNA Splicing in the Retina: Insights and Perspectives
Keuthan, C. J., Karma, S., & Zack, D. J. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041313 · Cited by 16
Antisense RNA Therapeutics: A Brief Overview
Arechavala‐Gomeza, V., & Garanto, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_2 · Cited by 11
Self-citationState of the Art on Inherited Retinal Dystrophies: Management and Molecular Genetics
Nebbioso, M., Artico, M., Gharbiya, M., Mannocci, A., Limoli, P. G., Iannetta, D., & Donato, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103526 · Cited by 9
“…for the development of advanced diagnostic, management, therapeutic, and research strategies, which will significantly improve the outcomes for patients with visual disabilities, facilitating a proper approach to the well-being of individuals and their social and educational integration [4–7].”
Gene Augmentation for Autosomal Dominant CRX-Associated Retinopathies
Sun, C., & Chen, S. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-27681-1_21 · Cited by 9
Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 12
“RNAse H-dependent antisense oligonucleotides (AONs) degrade transcripts in a specific and sometimes allele-specific manner [70].”
Genetics of retinitis pigmentosa and other hereditary retinal disorders in Western Switzerland
Conti, G. M., Vaclavik, V., Rivolta, C., Escher, P., Schorderet, D. F., Munier, F. L., & Tran, H. V. (2023) · Ophthalmic Research · doi:10.1159/000536036 · Cited by 8
“In recent years, many studies have been underway for potential therapies [4], including gene therapies such as voretigene neparvovec-rzyl (Luxturna ® ), a viral vector carrying the RPE65 gene, which is commercially available since December 2017 after FDA approval [5].”
BackgroundRetinitis Pigmentosa and Allied Diseases
Alemán, T. S. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_1-1 · Cited by 8
Vázquez-Domínguez, I., Öktem, M., Winkelaar, F. A., Nguyen, T. H., Hoogendoorn, A. D. M., Roschi, E., Astuti, G., Timmermans, R., Suárez-Herrera, N., Bruno, I., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102345 · Cited by 7
“75 However, the main limitation of using AONs to treat these splicing defects is that the molecules are mainly variant speci fi c, limiting the number of patients that can be treated with a single therapeutic molecule.”
Self-citationLiu, Z., Zeng, F., Zhang, Y., Liu, Y., Li, Z., & Liu, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.905516 · Cited by 6
“usage of neurotrophic factors, gene therapy, retinal transplantation, stem cells, or drugs (Sieving et al., 2006; Gasparini et al., 2019; Vazquez-Dominguez et al., 2019).”
BackgroundNanoparticles for triggering gene expression and osteoconductivity
Chakraborty, P., Chowdhury, S., & Mondal, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95134-0.00014-6 · Cited by 6
Oh, R., Woo, S. J., & Joo, K. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06309-5 · Cited by 6
“Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of diseases characterized by the progressive loss of photoreceptors and/or retinal pigment epithelial cells [1–3] that affect approximately 1 in 2000–3000 people [4, 5].”
Panneman, D. M., Hitti‐Malin, R. J., McKibbin, M., de Bruijn, S. E., Boonen, E. G. M., Vincent, A. L., Vargas, G. V., Corominas, J., Astuti, G., Gilissen, C., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.19 · Cited by 6
Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient
Elsayed, M. E. A. A., Kaukonen, M. K., Kiraly, P., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2022) · Genes · doi:10.3390/genes13112103 · Cited by 6
“Serotypes of adeno-associated viruses (AAV) used in clinical trials of inherited retinal disease (IRD) thus far include AAV2/5, AAV2/8 and AAV8 [36].”
MethodAntisense Oligonucleotide Therapeutics for Neurodegenerative Disorders
Testa, C. M. (2021) · Current Geriatrics Reports · doi:10.1007/s13670-020-00341-7 · Cited by 4
Suárez-Herrera, N., Riswick, I. B., Vázquez-Domínguez, I., Duijkers, L., Karjosukarso, D. W., Piccolo, D., Bauwens, M., Baere, E. B. W. D., Cheetham, M. E., Garanto, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.019 · Cited by 5
Self-citationGong, X., & Hertle, R. W. (2024) · Life · doi:10.3390/life14111356 · Cited by 4
Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date
Kalatzis, V., Roux, A., & Meunier, I. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00558-y · Cited by 5
Cabrera‐Aguas, M., Downie, L. E., Munsie, M., Girolamo, N. D., O’Connor, M. D., & Watson, S. L. (2022) · Clinical and Experimental Optometry · doi:10.1080/08164622.2022.2102409 · Cited by 3
“- 19,20 For DED, there are ongoing Phase 1/2 clinical trials with mesenchymal SCs (MSC) to investigate their efficacy and safety in patients with aqueous-deficient DED, and dry eye associated with Sjögren’s syndrome.”
Fujinami, K., Fujinami‐Yokokawa, Y., Yang, L., Liu, X., Arno, G., Pontikos, N., & East Asia Inherited Retinal Disease Society (EAIRDs) Study Group (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_9 · Cited by 4
Delivery of Antisense Oligonucleotides to the Mouse Retina
Garanto, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_22 · Cited by 3
Self-citationArias-Uribe, J., Llano-Naranjo, Y., Suárez-Escudero, J. C., Jaramillo-Cerezo, A., Yepes, V. T., & Franco-Sánchez, I. (2021) · Revista Mexicana de Oftalmología · doi:10.24875/rmo.m21000202 · Cited by 27
An Overview on the Genetic Etiology, Testing, and Therapeutic Options for Retinitis Pigmentosa
Srikrupa, N. N., Gnanasekaran, H., Kandeeban, S., Sundaramurthy, S., & Sripriya, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4247-0_12 · Cited by 4
Wang, Y., Chen, J., Zhang, M., Yu, S., Gong, Y., Lin, F., Wu, Y., Liu, W., Sun, J., Li, T., et al. (2023) · Retina · doi:10.1097/iae.0000000000003931 · Cited by 2
“29 We are expecting to provide new perspectives for the prognosis of ABCA4 - related retinopathy and may provide guidance for future treatments.”
BackgroundUsing Small Molecules to Reprogram RPE Cells in Regenerative Medicine for Degenerative Eye Disease
Rzhanova, L. A., Алпеева, Е. В., & Aleksandrova, M. A. (2024) · Cells · doi:10.3390/cells13231931 · Cited by 3
Cloud-based genomics pipelines for ophthalmology: reviewed from research to clinical practice
Wong, D., Olivera, M., Yu, J., Szabó, A., Moghul, I., Balaskas, K., Luben, R., Khawaja, A. P., Pontikos, N., & Keane, P. A. (2021) · Modeling and Artificial Intelligence in Ophthalmology · doi:10.35119/maio.v3i1.115 · Cited by 2
Crawford, D. K., Vanlandingham, P. A., Schneider, S. M., & Goddeeris, M. M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108274 · Cited by 1
From Cellular to Metabolic: Advances in Imaging of Inherited Retinal Diseases
Parameswarappa, D. C., Kulkarni, A., Sahoo, N. K., Padhy, S. K., Singh, S. R., Héon, E., & Chhablani, J. K. (2024) · Diagnostics · doi:10.3390/diagnostics15010028 · Cited by 5
Real-World Comparison of Overall Survival Among Patients With and Without Inherited Retinal Diseases
Lam, B. L., Mendoza-Santiesteban, C. E., Pilon, D., Milentijevic, D., Morrison, L., Schwartzbein, S., Eynde, C. V., Lafeuille, M., Lefèbvre, P., & Gregori, N. Z. (2026) · Vision · doi:10.3390/vision10010015 · Cited by 1
Retinitis Pigmentosa and Allied Diseases
Alemán, T. S. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_1-2 · Cited by 1
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737148
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737133
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737136
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737139
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737145
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737142
Владимирович, М. А., Анатольевна, С. С., Nikitin, S., Adyan, T., Akhkiamova, M., Borovikov, A. O., Buharova, T., Efimova, I. E., Zharkov, P., Kadyshev, V. V., et al. (2026) · doi:10.29039/978-5-94472-329-1-02-2026
Metadata
- Authors
- Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J.
- Affiliations
- Radboud University Nijmegen (NL)
- Corresponding author
- Garanto, Alejandro
- Collin, Rob W. J.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-08-28
- Volume
- 10
- Issue
- 9
- Pages
- 654
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6770110
- OpenAlex
- W2971284229
- Cited by
- 80
- References
- 235
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 19 · 2021: 24 · 2020: 11 · 2019: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (PPA-0517-0717-RAD)
- UitZicht (2015-31, 2018-21)
- ZonMw (Off Road 91215203)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- inherited retinal disease, gene therapy, gene augmentation therapy, RPE65, genome editing, optogenetics, RNA therapeutics, retinal degeneration, molecular therapy
- MeSH terms
- Clinical Trials as Topic, Humans, Retinal Degeneration, Genetic Therapy, Gene Transfer Techniques, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.